User profiles for Edwards Pradenas
 | Edwards PradenasIrsiCaixa AIDS Research Institute Verified email at irsicaixa.es Cited by 852 |
[HTML][HTML] Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity
…, N Izquierdo-Useros, C Ávila-Nieto, E Pradenas… - Biochemical and …, 2021 - Elsevier
The magnitude and the quality of humoral responses against SARS-CoV-2 have been
associated with clinical outcome. Although the elicitation of humoral responses against different …
associated with clinical outcome. Although the elicitation of humoral responses against different …
[HTML][HTML] Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses
…, NR Melero, D Parras, P Serra, E Pradenas… - Nature …, 2021 - nature.com
Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and the individual characteristics
influencing it, including the impact of pre-existing antibodies to human coronaviruses …
influencing it, including the impact of pre-existing antibodies to human coronaviruses …
[HTML][HTML] High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial
…, J Ara, AF Arcarons, M Farré, E Pradenas… - The Lancet …, 2022 - thelancet.com
Background Convalescent plasma has been proposed as an early treatment to interrupt the
progression of early COVID-19 to severe disease, but there is little definitive evidence. We …
progression of early COVID-19 to severe disease, but there is little definitive evidence. We …
[PDF][PDF] Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
E Pradenas, B Trinité, V Urrea, S Marfil, C Ávila-Nieto… - Med, 2021 - cell.com
Background Understanding mid-term kinetics of immunity to SARS-CoV-2 is the cornerstone
for public health control of the pandemic and vaccine development. However, current …
for public health control of the pandemic and vaccine development. However, current …
[HTML][HTML] SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity
The protective effect of neutralizing antibodies in SARS-CoV-2 infected individuals is not yet
well defined. To address this issue, we have analyzed the kinetics of neutralizing antibody …
well defined. To address this issue, we have analyzed the kinetics of neutralizing antibody …
Mouthwashes with CPC reduce the infectivity of SARS-CoV-2 variants in vitro
…, B Trinité, E Pradenas… - Journal of dental …, 2021 - journals.sagepub.com
Oral mouthwashes decrease the infectivity of several respiratory viruses including SARS-CoV-2.
However, the precise agents with antiviral activity in these oral rinses and their exact …
However, the precise agents with antiviral activity in these oral rinses and their exact …
[HTML][HTML] An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses
…, V Urrea, B Trinité, R Ortiz, E Pradenas… - npj Vaccines, 2023 - nature.com
Antigen display on the surface of Virus-Like Particles (VLPs) improves immunogenicity
compared to soluble proteins. We hypothesised that immune responses can be further improved …
compared to soluble proteins. We hypothesised that immune responses can be further improved …
[HTML][HTML] Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated …
Background A SARS-CoV-2 protein-based heterodimer vaccine, PHH-1V, has been shown
to be safe and well-tolerated in healthy young adults in a first-in-human, Phase I/IIa study …
to be safe and well-tolerated in healthy young adults in a first-in-human, Phase I/IIa study …
[PDF][PDF] Clinical course impacts early kinetics, magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
E Pradenas, B Trinité, V Urrea, S Marfil… - Cell Reports …, 2022 - cell.com
To understand the determinants of long-term immune responses to severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and the concurrent impact of vaccination and …
syndrome coronavirus 2 (SARS-CoV-2) and the concurrent impact of vaccination and …
[HTML][HTML] First detection of SARS-CoV-2 delta (B. 1.617. 2) variant of concern in a dog with clinical signs in Spain
Several cases of naturally infected dogs with severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) have been reported despite the apparently low susceptibility of this …
2 (SARS-CoV-2) have been reported despite the apparently low susceptibility of this …